EMILY
MULLIN

​

A freelance science journalist and fall 2021 Knight Science Journalism fellow at MIT, my work explores the intersection of biotechnology and society. Most recently, I was a staff writer at OneZero, Medium's in-house tech and science publication, where I broke stories on the first planned pig-to-human kidney transplants, the disastrous effects of CRISPR on human embryos, and a dubious $1 million pay-to-participate study to reverse aging. At OneZero, I also wrote deep dives on a government program to make radiation-proof soldiers, the effort to design a universal coronavirus vaccine, and the ethics of using gene therapy to "cure" inherited deafness. 

 

Previously, I was the associate editor for biomedicine at MIT Technology Review, where I won a Newsbrief Award from the D.C. Science Writers Association and was named a finalist for a National Institute for Health Care Management Journalism Award.

 

​My stories have also appeared in The Washington Post, New York Times, Wall Street Journal, Scientific American, National Geographic, The Atlantic, Smithsonian Magazine, WIRED, and Fortune, among others.  

 

I started my career at the Baltimore Business Journal, where I followed the high-profile case of a Maryland cardiologist accused of implanting unnecessary heart stents in patients. I earned my bachelor's degree in journalism at Ohio University and a master's in science writing from Johns Hopkins. After more than a decade in the Washington, D.C., area, I recently returned to my Western Pennsylvania roots and now reside in Pittsburgh.

​

​

​